Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.
about
Nanotechnology: Future of OncotherapyQuantifying progression and regression of thrombotic risk in experimental atherosclerosisAnnotating the structure and components of a nanoparticle formulation using computable string expressionsRecent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions.Assessing the barriers to image-guided drug delivery.Manganese-based MRI contrast agents: past, present and future.Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.Physicochemical signatures of nanoparticle-dependent complement activation.Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery.alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbitsApplications of nanomaterials as vaccine adjuvants.Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles.Nanomedicine in cardiovascular therapy: recent advancements.Inspired by nature: fundamentals in nanotechnology design to overcome biological barriers.Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms.Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis.Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles.Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities.Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum.An unmet clinical need: The history of thrombus imaging.Main trends of immune effects triggered by nanomedicines in preclinical studies
P2860
Q26801067-9FF2F686-3DC6-4924-89AE-5D6225B30C1BQ27318779-85B194B7-2270-4E87-BCD7-1A27082837F4Q28395833-DF4C364C-EB67-4282-BDF7-5EDE4A5711EEQ30385272-0D2F09AE-E5B6-49B2-BEBA-EEB1AE7647C7Q30422169-8476105E-5AB9-45E0-99DF-3D87162E43B1Q30461349-7BF8064F-DD6F-4BC1-8EB0-A5E3D22DEF84Q33925578-B622BA9E-2793-4558-8F5F-5098DB38E5B3Q34218533-D2B4FAAB-13B3-4C69-BB99-1B4F1201E4E5Q34698633-8FFE0512-234A-4CD9-85C2-988701EB17E1Q34785222-2431330B-8A44-4E77-8C6E-18B55BC351A3Q35317271-B3C129EB-6DA9-44B9-977E-F63F26AE13B9Q36483514-CD082D79-B1A1-4339-BE15-AD0218999981Q37159697-9414214D-6082-4E25-8FE1-CABB59850907Q37323288-93B46926-E051-4748-AC5B-53F62D37EECFQ37577978-E49D3500-BD4A-42A6-B1D4-46867E85A483Q37666126-640CB442-CB5F-4AA5-8E44-6EBB170B306FQ38034812-0EEB8395-C650-4303-8BCB-C49375C48842Q38074461-E07FD87C-7CDB-42E8-B0CB-6B11130B9A3DQ38112504-98EE1B07-4297-4C5E-8338-68DF2F1C9A0CQ38940828-2AEC3565-B919-4A8A-A4C8-6205A0E31528Q41860441-0E534B5A-E393-415F-B81D-7EF22F7B0198Q41879624-E46CF794-24D8-4A9E-AB8E-A4AFAFC7891AQ42592314-CAE81A8C-06DE-4FA4-9396-2EE3167FBCFAQ43043648-3A771E5A-F847-4836-A685-E64C3235B1DEQ47177380-3EA198A6-8E0A-49D0-84DA-C488104508B2Q57074417-DCA31F0B-74E3-4A0D-81D4-F16AFC725566
P2860
Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@ast
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@en
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@nl
type
label
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@ast
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@en
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@nl
prefLabel
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@ast
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@en
Variable antibody-dependent ac ...... holipid nanoparticle surfaces.
@nl
P2093
P2860
P356
P1476
Variable antibody-dependent ac ...... pholipid nanoparticle surfaces
@en
P2093
Christine T N Pham
Christopher M Lubniewski
Dennis E Hourcade
Gregory M Lanza
J Kendall Killgore
Jennifer L Huang
Lynne M Mitchell
Otto F Schall
Samuel A Wickline
P2860
P304
P356
10.1074/JBC.M110.180760
P407
P50
P577
2010-11-03T00:00:00Z